5-lipoxygenase inhibitors - Patent and literature activity during 2001 - 2004

Expert Opinion on Therapeutic Patents

Volumn 16, Issue 1, 2006, Pages 13-26

  Pommery, Nicole ^a   Massingham, Roy ^b   Hénichart, Jean Pierre ^a  

^a Faculté des Sciences Pharmaceutiques et Biologiques Université de Lille   (France)

^b Pharma C   (France)

Author keywords

5 lipoxygenase; Cancer; Inflammation; Inhibitors

Indexed keywords

2 [2 PROPYL 3 [3 [2 ETHYL 4 (4 FLUOROPHENYL) 5 HYDROXYPHENOXY]PROPOXY]PHENOXY]BENZOIC ACID; 2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 AMINO 1 (3 TRIFLUOROMETHYLPHENYL) 2 PYRAZOLINE; 6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 1 METHYL 2 QUINOLONE; ARACHIDONATE 5 LIPOXYGENASE; ATRELEUTON; CYCLOOXYGENASE 2 INHIBITOR; DEFERIPRONE; DOCEBENONE; L 697198; LICOFELONE; LIPOXYGENASE INHIBITOR; LONAPALENE; MONTELUKAST; N [5 (4 FLUOROPHENOXY) 2 THIENYL]METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; NORDIHYDROGUAIARETIC ACID; OXYGENASE INHIBITOR; PHENIDONE; PHENYLACETIC ACID DERIVATIVE; PRANLUKAST; PRIFELONE; QUERCETIN; S 2474; TEBUFELONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON;

ALLERGIC DISEASE; ASTHMA; CANCER THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME REGULATION; EVIDENCE BASED MEDICINE; HUMAN; IC 50; INFLAMMATORY DISEASE; LIVER TOXICITY; MEDICAL LITERATURE; NONHUMAN; PANCREAS CANCER; PATENT; REVIEW;

EID: 30344466019     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.16.1.13     Document Type: Review

References (58)

1. WERZ O, STEINHILBER D: Development of 5-lipoxygenase inhibitors - lessons from cellular enzyme regulation. Biochem. Pharmacol. (2005) 70:327-333.
2. BIGBY TD: The yin and the yang of 5-lipoxygenase pathway activation. Mol. Pharmacol. (2002) 62(2):200-202.
3. PETERS-GOLDEN M, BROCK TG: 5-Lipoxygenase and FLAP. Prostaglandins Leukot. Essent. Fatty Acids (2003) 69:99-109.
4. SERHAN C, HAMBERG M, SAMUELSSON B: Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc. Natl. Acad. Sci. USA (1984) 81:5335-5339.
5. SERHAN CN: Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukot. Essent. Fatty Acids (2005) 73:141-162.
6. ROWLINSON SW, CREWS BC, GOODWIN DC, SCHNEIDER C, GIERSE JK, MARNETT LJ: Spatial requirements for 15-(R)-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid synthesis within the cyclooxygenase active site of murine COX-2. Why acetylated COX-1 does not synthesize 15-(R)-HETE. J. Med. Chem. (2000) 275:6586-6591.
7. PETASIS NA, AKRITOPOULO-ZANZE I, FOKIN VV et al.: Design, synthesis and bioactions of novel stable mimetics of lipoxins and aspirin-triggered lipoxins. Prostaglandins Leukot. Essent. Fatty Acids (2005) 73:301-321.
8. LEVY BD: Lipoxins and lipoxin analogs in asthma. Prostaglandins Leukot. Essent. Fatty Acids (2005) 73:231-237.
9. 4 analogs. Prostaglandins Leukot. Essent. Fatty Acids (2005) 73:245-250.
10. CHIANG N, ARITA M, SERHAN CN: Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukot. Essent. Fatty Acids (2005) 73:163-177.
11. MCMAHON B, MITCHELL D, SHATTOCK R, MARTIN F, BRADY HR, GODSON C: Lipoxin, leukotriene, and PDGF receptors cross-talk to regulate mesangial cell proliferation. FASEB J. (2002) 16:1817-1819.
12. MCMILLAN RM: Leukotrienes in respiratory disease. Paediatr. Respir. Rev. (2001) 2(3):238-244.
13. WENZEL SE: The role of leukotrienes in asthma. Prostaglandins Leukot. Essent. Fatty Acids (2003) 69:145-155.
14. DRAZEN J: Clinical pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors. Am. J. Respir. Crit. Care Med. (1998) 157:233-237.
15. GARCIA-MARCOS L, SCHUSTER A: Antileukotrienes in asthma: present situation. Expert Opin. Pharmacother (2001) 2(3):441-466.
16. GARCIA-MARCOS L, SCHUSTER A, PEREZ-YARZA EG: Benefit-risk assessment of antileukotrienes in the management of asthma. Drug Saf. (2003) 26(7):483-518.
17. PARNES SM: The role of leukotriene inhibitors in allergic rhinitis and paranasal sinusitis. Curr. Allergy Asthma Rep. (2002) 2(3):239-244.
18. BUSSE W, KRAFT M: Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. Chest (2005) 127(4):1312-1326.
19. LINTON MF, FAZIO S: Cyclooxygenase-2 and inflammation in atherosclerosis. Curr. Opin. Pharmacol. (2004) 4(2):116-123.
20. SPANBROEK R, HABENICHT AJ: The potential role of antileukotriene drugs in atherosclerosis. Drug News Perspect. (2003) 16(8):485-489.
21. VILA L: Cyclooxygenase and 5-lipoxygenase pathways in the vessel wall: role in atherosclerosis. Med. Res. Rev. (2004) 24(4):399-424.
22. MEHRABIAN M, ALLAYEE H: 5-Lipoxygenase and atherosclerosis. Curr. Opin. Lipidol. (2003) 14:447-457.
23. DI GENNARO A, CARNINI C, BUCCELLATI C et al.: Cysteinyl-leukotriene receptor activation in brain inflammatory reactions and cerebral edema formation: a role for transcellular biosynthesis of cysteinyl leukotrienes. FASEB J. (2004) 18(7):842-844.
24. STEELE VE, HOLMES CA, HAWK ET et al.: Potential use of lipoxygenase inhibitors for cancer chemoprevention. Expert Opin. Investig. Drugs (2000) 9(9):2121-2138.
25. LI N, SOOD S, WANG S et al.: Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib. Clin. Cancer Res. (2005) 11:2089-2096.
26. HOQUE A, LIPPMAN SM, WU TT et al.: Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis (2005) 26:785-791.
27. MATSUYAMA M, YOSHIMURA R, MITSURASHI M et al.: 5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway. Oncol. Rep. (2005) 14:73-79.
28. HENNIG R, GRIPPO P DING XZ et al.: 5-Lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions. Cancer Res. (2005) 65:6011-6016.
29. NIELSEN CK, OHD JF, WIKSTROM K et al.: The leukotriene receptor CysLT1 and 5-lipoxygenase are upregulated in colon cancer. Adv. Exp. Med. Biol. (2003) 525:201-204.
30. YE YN, WU WK, SHIN VY, CHO CH: A mechanistic study of colon cancer growth promoted by cigarette smoke extract. Eur. J. Pharmacol. (2005) 519:52-57.
31. NIE D, CHE M, GRIGNON D, TANG K, HONN KV: Role of eicosanoids in prostate cancer progression. Cancer Metastasis Rev. (2001) 20:195-206.
32. MATSUYAMA M, YOSHIMURA R, MITSUHASHI M et al.: Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors. Int. J. Oncol. (2004) 24(4):821-827.
33. SHAPPELL SB, GUPTA RA, MANNING S et al.: 15S-hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor γ and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res. (2001) 61:497-503.
34. PHAM H, BANERJEE T, NALBANDIAN GM, ZIBOH VA: Activation of peroxisome proliferator-activated receptor (PPAR)-γ by 15S-hydroxyeicosatrienoic acid parallels growth suppression of androgen-dependent prostatic adenocarcinoma cells. Cancer Lett. (2003) 189:17-25.
35. CHARLIER C, MICHAUX C: Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur. J. Med. Chem. (2003) 38:645-659.
36. LIU ZD, KAYYALI R, HIDER RC, PORTER JB, THEOBALD AE: Design, synthesis, and evaluation of novel 2-substituted 3-hydroxypyridin-4-ones: structure-activity investigation of metalloenzyme inhibition by iron chelators. J. Med. Chem. (2002) 45:631-639.
37. MANO T, STEVENS RW, ANDO K et al.: Novel imidazole compounds as a new series of potent, orally active inhibitors of 5-lipoxygenase. Bioorg. Med. Chem. (2003) 11:3879-3887.
38. MANO T, OKUMURA YO, SAKAKIBARA M et al.: 4-[5-Fluoro-3-[4-(2-methyl-1H-imidazol-1-yl) benzyloxy]phenyl]-3,4,5,6-tetrahydro-2H-pyran-4-carboxamide, an orally active inhibitor of 5-lipoxygenase with improved pharmacokinetic and toxicology characteristics. J. Med. Chem. (2004) 47:720-725.
39. MANO T, STEVENS RW, OKUMURA Y et al.: 5-Lipoxygenase inhibitors: convenient synthesis of 4-[3-(4-heterocyclylphenylthio)phenyl]-3,4, 5,6-tetrahydro-2H-pyran-4-carboxamide analogues. Bioorg. Med. Chem. Lett. (2005) 15:2611-2615.
40. MANO T, STEVENS RW, ANDO K et al.: Optimization of imidazole 5-lipoxygenase inhibitors and selection and synthesis of a development candidate. Chem. Pharm. Bull (2005) 53:965-973
41. 4 receptor antagonist. J. Med. Chem. (1995) 38:4411-4432.
42. 4 receptor antagonist LY293111; in vitro studies. J. Pharm. Exp. Ther. (1999) 288:286-294.
43. DING XZ, TALAMONTI MS, BELL RH JR, ADRIAN TE: A novel antipancreatic cancer agent, LY293111. Anticancer Drugs (2005) 16:467-473.
44. 2 receptors. Org. Biomol. Chem. (2004) 2:3427-3431.
45. SCHNEIDER I, BUCAR F: Lipoxygenase inhibitors from natural plant sources. Part 1: medicinal plants with inhibitory activity on arachidonate 5-lipoxygenase and 5-lipoxygenase/cyclooxygenase. Phytother. Res. (2005) 19:81-102.
46. FIORUCCI S, MELI R, BUCCI M, CIRINO G: Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? Biochem. Pharmacol. (2001) 62(11):1433-1438.
47. LEVAL X, JULEMONT F, DELARGE J, PIROTTE, B, DOGNE JM: New trends in dual 5-LOX/COX inhibition. Curr. Med. Chem. (2002) 9(9):941-962.
48. ROMANO M, CLARIA J: Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J. (2003) 17:1986-1995.
49. RUIZ J, PEREZ C, POUPLANA R: QSAR study of dual cyclooxygenase and 5-lipoxygenase inhibitors 2,6-di-tert-butylphenol derivatives. Bioorg. Med. Chem. (2003) 11:4207-4216.
50. BARBEY S, GOOSSENS L, TAVERNE T et al.: Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor. Bioorg. Med. Chem. Lett. (2002) 12:779-782.
51. POMMERY N, TAVERNE T, TELLIEZ A et al.: New COX-2/5-LOX inhibitors: apoptosis-inducing agents potentially useful in prostate cancer chemotherapy. J. Med. Chem. (2004) 47:6195-6206.
52. SELIG WM, BAYLESS L, LIBERTINE L et al.: Pharmacology of a novel, dual-function anti-inflammatory agent with histamine Type 1 receptor antagonist and 5-lipoxygenase inhibitor activity. Chest (2003) 123:371S.
53. SCANNELL RT, DIFFERDING E, TALAGA P: Dual acting antihistaminergic agents. Mini Rev. Med. Chem. (2004) 4(9):923-933.
54. 1 receptor antagonist activity. Bioorg. Med. Chem. Lett. (2004) 14:2265-2268.
55. LEWIS TA, BAYLESS L, DIPESA AJ et al.: 5-Lipoxygenase inhibition by N-hydroxycarbamates in dual-function compounds. Bioorg. Med. Chem. Lett. (2005) 15:1083-1085.
56. POMMERY J, POMMERY N, HENICHART JP: Modification of eicosanoid profile in human blood treated by dual COX/LOX inhibitors. Prostaglandins Leukot. Essent. Fatty Acids (2005) On line.
57. LEVY BD, BONNANS C, SILVERMAN ES, PALMER LJ, MARIGOWDA G, ISRAEL E: Diminished lipoxin biosynthesis in severe asthma. Am. J. Respir. Crit. Care Med. (2005) 172:824-830.
58. VACHIER I, BONNANS C, CHAVIS C et al.: Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound. J. Allergy Clin. Immunol. (2005) 115:55-60.